CPRX Stock Recent News

Catalyst (CPRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang for their buck right now?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here we present four stocks, GLDD, TILE, CPRX and STRL, with solid net profit margins that can contribute to making a strong portfolio.

Catalyst Pharmaceuticals, Inc. (CPRX), keeps growing, bringing in Big Money.

Catalyst (CPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Does Catalyst Pharmaceutical (CPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.